600420 Shanghai Shyndec Pharmaceutical
- 12.28
- -0.16-1.29%
Shanghai Shyndec Pharmaceutical News
Announcement Regarding Holding Subsidiary Pharmaceutical Passed Generic Drug Consistency Evaluation
Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement regarding the resignation of senior management personnel.
Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.
Announcement Regarding Retirement and Departure of Senior Management.
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement on Obtaining Approval Notice for Supplementary Application of Pharmaceutical
Investor Relations Activity Record Form.
Announcement on the Progress of the Pharmaceutical Marketing Authorization Transfer Contract.
Announcement of the performance forecast for the first half of 2024.
Announcement regarding the holding subsidiary's acquisition of pharmaceutical registration certificate.
CITIC Securities Co., Ltd.'s verification opinion on the non-publicly issued restricted shares of Shanghai Modern Pharmaceutical Co., Ltd. for listing and circulation.
Announcement on the Listing and Trading of Restricted Shares for Non-public Issuance.
Announcement regarding obtaining overseas marketing authorization for injectable cefuroxime sodium.
Announcement regarding the holding subsidiary's acquisition of pharmaceutical registration certificate.
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement on the full subsidiary's receipt of approval for active pharmaceutical ingredient marketing application
Announcement of the implementation of equity distribution in 2023.
Announcement regarding the active pharmaceutical ingredient of the wholly-owned subsidiary obtaining CEP certificate.
Analysis
Price Target
No Data
